Skip to main content
LLY
NYSE Life Sciences

Eli Lilly Completes $9.0 Billion Debt Offering, Funds Centessa Acquisition

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1,016.97
Mkt Cap
$959.512B
52W Low
$623.78
52W High
$1,133.95
52W Position info
63% above low
Off High info
10% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

LLY sits 63% above its 52-week low of $623.78.

Summary

Eli Lilly completed a $9.0 billion debt offering, raising approximately $8.94 billion in net proceeds, with a significant portion explicitly tied to financing the previously announced Centessa acquisition.


Key Events · Financing and Capital Events · LLY

  • Completed $9.0 Billion Debt Offering

    Eli Lilly completed an offering of various Floating Rate Notes and Fixed Rate Notes totaling $9.0 billion in aggregate principal amount.

  • Raised $8.94 Billion in Net Proceeds

    The company received approximately $8.94 billion in net proceeds from the debt offering, after deducting underwriting discounts.

  • Financing Linked to Centessa Acquisition

    A significant portion of the notes ($6.25 billion) are subject to a special mandatory redemption if the Centessa Acquisition is not consummated by March 31, 2027, explicitly linking the financing to the previously announced $6.3 billion acquisition.

  • Diverse Note Maturities and Rates

    The offering includes both floating and fixed-rate notes with maturities ranging from 2028 to 2066, diversifying the company's debt profile.


Analysis · LLY · Life Sciences

Eli Lilly has successfully completed a substantial debt offering, raising approximately $8.94 billion in net proceeds. This capital raise is significant for funding the company's strategic growth initiatives. A key detail is the special mandatory redemption clause for $6.25 billion of the notes, explicitly linking this financing to the previously announced Centessa acquisition. This demonstrates the company's commitment to its M&A strategy and provides the necessary capital to execute it, following a period of strong operational performance and product development.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LLY was trading at $1,016.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $959.5B. The 52-week trading range was $623.78 to $1,133.95. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,431.00 info
Change: -$21.69 (-1%) info
Market Cap: $1.343T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,431.00 info
Change: -$16.85 (-1%) info
Market Cap: $1.343T info
LLY
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1,411.12
Real-time Price: $1,431.00 info
Change: +$19.88 (+1%) info
Market Cap: $1.343T info
LLY
Nov 09, 2026, 10:23 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1,394.15
Real-time Price: $1,431.00 info
Change: +$36.85 (+3%) info
Market Cap: $1.343T info
LLY
Nov 06, 2026, 6:45 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,346.00
Real-time Price: $1,431.00 info
Change: +$85.00 (+6%) info
Market Cap: $1.343T info